|
1 Indications And Usage Nevirapine Extended-Release Tablets Are Indicated In Combination With Other Antiretroviral Agents For The Treatment Of Human Immunodeficiency Virus (Hiv-1) Infection In Adults And Pediatric Patients 6 Years Of Age Or Older With A Body Surface Area (Bsa) Of 1.17 M 2 Or Greater [See Clinical Studies (14.1 , 14.2) ] . Limitations Of Use Based On Serious And Life-Threatening Hepatotoxicity Observed In Controlled And Uncontrolled Trials, Nevirapine Extended-Release Tablets Are Not Recommended To Be Initiated, Unless The Benefit Outweighs The Risk, In: • Adult Females With Cd4 + Cell Counts Greater Than 250 Cells/mm 3 Or • Adult Males With Cd4 + Cell Counts Greater Than 400 Cells/mm 3 [See Warnings And Precautions (5.1) ] . • Nevirapine Extended-Release Tablets Are An Nnrti Indicated In Combination With Other Antiretroviral Agents For The Treatment Of Human Immunodeficiency Virus (Hiv-1) Infection In Adults And Pediatric Patients 6 Years Of Age Or Older With A Bsa Of 1.17 M 2 Or Greater. (1) Limitations Of Use: Based On Serious And Life-Threatening Hepatotoxicity Observed In Controlled And Uncontrolled Trials, Nevirapine Extended-Release Tablets Are Not Recommended To Be Initiated, Unless The Benefit Outweighs The Risk, In: • Adult Females With Cd4 + Cell Counts Greater Than 250 Cells/mm 3 • Adult Males With Cd4 + Cell Counts Greater Than 400 Cells/mm 3 (1 , 5.1)
|